Key result
In a rat model, adriamycin administration over 10 weeks successfully induced non-ischemic cardiomyopathy, significantly decreasing fractional shortening from 52.8% to 34.3% (p < 0.001).
Why the study?
Does intravenous adriamycin induce a reliable model of non-ischemic cardiomyopathy in rats that can be serially evaluated by transthoracic echocardiography?
Does intravenous adriamycin induce a reliable model of non-ischemic cardiomyopathy in rats that can be serially evaluated by transthoracic echocardiography?
Absolute Event Rate: 34.3% vs 52.8%
p-value: p=< 0.001
Adriamycin administered at 2.5 mg/kg intravenously weekly for 10 weeks creates a reliable rat model of non-ischemic dilated cardiomyopathy that can be accurately monitored using transthoracic echocardiography.
No takes yet. Share an insight, caveat, or question.
Supports adriamycin rat models for preclinical cardiomyopathy research; leaves open translation to human non-ischemic HF.
Ernst R. Schwarz (1998) studied Non-ischemic cardiomyopathy (n=54). Adriamycin vs. Baseline was evaluated on Fractional shortening (p=< 0.001). In a rat model, adriamycin administration over 10 weeks successfully induced non-ischemic cardiomyopathy, significantly decreasing fractional shortening from 52.8% to 34.3% (p < 0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: